Guillaume Pavlovic
Head of Unit, Genetic Engineering and Model Validation
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Guillaume Pavlovic is the Head of Unit for Genetic Engineering and Model Validation at the Institut Clinique de la Souris - ICS - IGBMC - CELPHEDIA in France. His research focuses on genetic engineering, particularly in the context of mammalian genetics and genome editing techniques. Recent publications include studies on knockout mouse lines and the implications of genetic modifications, shedding light on critical genes related to ocular phenotypes and embryonic development.
Articles (10)
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
The French mouse clinic (Institut Clinique de la Souris; ICS) has produced more than 2000 targeting vectors for ‘à la carte’ mutagenesis in C57BL/6N mice. Although most of the vectors were used successfully for homologous recombination in murine embryonic stem cells (ESCs), a few have failed to target a specific locus after several attempts. We show here that co-electroporation of a CRISPR plasmid with the same targeting construct as the one that failed previously allows the systematic achievement of positive clones. A careful validation of these clones is, however, necessary as a significant number of clones (but not all) show a concatemerization of the targeting plasmid at the locus. A detailed Southern blot analysis permitted characterization of the nature of these events as standard long-range 5′ and 3′ PCRs were not able to distinguish between correct and incorrect alleles. We show that a simple and inexpensive PCR performed prior to ESC amplification allows detection and elimination of those clones with concatemers. Finally, although we only tested murine ESCs, our results highlight the risk of mis-validation of any genetically modified cell line (such as established lines, induced pluripotent stem cells or those used for ex vivo gene therapy) that combines the use of CRISPR/Cas9 and a circular double-stranded donor. We strongly advise the CRISPR community to perform a Southern blot with internal probes when using CRISPR to enhance homologous recombination in any cell type, including fertilized oocytes.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (7)
Marie-Christine Birling
University of Strasbourg
Gemma Codner
University of Oxford
Yann Herault
University of Strasbourg
Mahmood Amiry-Moghaddam
Professor
University of Oslo
James M. Amos-Landgraf
University of Missouri School of Medicine
Cheryl Ackert-Bicknell
Associate Professor
University of Colorado Hospital
Fabien Delerue
Macquarie University
Make your next move.
Prepare your application
Review drafts before you send them.